Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nic G Reitsam

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Plos Medicine|April 9, 2026
Spatial omics and AI for clinically actionable cancer biomarkersNic G Reitsam
NPJ Precision Oncology|July 31, 2024
The SARIFA biomarker in the context of basic research of lipid-driven cancersBruno Märkl, Nic G Reitsam, Przemyslaw Grochowski, et al.
Clinical Nuclear Medicine|June 5, 2025
[ 18 F]FDG PET/CT in Primary Angiosarcoma of the ThyroidLisa Glantschnig, Nic G Reitsam, Timm Kleffel, et al.
Pathologie (Heidelberg, Germany)|October 4, 2024
[SARIFA-a new multi-entity biomarker]Bianca Grosser, Nic G Reitsam, Przmyslaw Grochowski, et al.
Clinical Nuclear Medicine|January 23, 2025
Intense FAP Expression of Ovarian Metastatic Breast Cancer Detected by [ 68 Ga]RTX-1363 PET/CTLisa Glantschnig, Nic G Reitsam, Malte Kircher Md, et al.
The Journal of Pathology. Clinical Research|April 16, 2026
HISTAI: a valuable dataset with a valuable lessonKatherine J Hewitt, Nic G Reitsam, Sebastian Foersch, et al.
BMC Cancer|June 26, 2024
The Concept of Stroma AReactive Invasion Front Areas (SARIFA) as a new prognostic biomarker for lipid-driven cancers holds true in pancreatic ductal adenocarcinomaPrzemyslaw Grochowski, Bianca Grosser, Florian Sommer, et al.
Cancer Gene Therapy|November 22, 2023
Novel biomarker SARIFA in colorectal cancer: highly prognostic, not genetically driven and histologic indicator of a distinct tumor biologyNic G Reitsam, Veselin Grozdanov, Chiara M L Löffler, et al.
Journal of Pathology Informatics|June 12, 2026
SCRIPT: Stratified clinical risk prediction from pathology reports using large language modelsChiara M L Loeffler, Nic G Reitsam, Fabian Wolf, et al.
BMC Cancer|January 12, 2024
SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancerJohanna S Enke, Matthias Groß, Bianca Grosser, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Plos Medicine|April 9, 2026
Spatial omics and AI for clinically actionable cancer biomarkersNic G Reitsam
NPJ Precision Oncology|July 31, 2024
The SARIFA biomarker in the context of basic research of lipid-driven cancersBruno Märkl, Nic G Reitsam, Przemyslaw Grochowski, et al.
Clinical Nuclear Medicine|June 5, 2025
[ 18 F]FDG PET/CT in Primary Angiosarcoma of the ThyroidLisa Glantschnig, Nic G Reitsam, Timm Kleffel, et al.
Pathologie (Heidelberg, Germany)|October 4, 2024
[SARIFA-a new multi-entity biomarker]Bianca Grosser, Nic G Reitsam, Przmyslaw Grochowski, et al.
Clinical Nuclear Medicine|January 23, 2025
Intense FAP Expression of Ovarian Metastatic Breast Cancer Detected by [ 68 Ga]RTX-1363 PET/CTLisa Glantschnig, Nic G Reitsam, Malte Kircher Md, et al.
The Journal of Pathology. Clinical Research|April 16, 2026
HISTAI: a valuable dataset with a valuable lessonKatherine J Hewitt, Nic G Reitsam, Sebastian Foersch, et al.
BMC Cancer|June 26, 2024
The Concept of Stroma AReactive Invasion Front Areas (SARIFA) as a new prognostic biomarker for lipid-driven cancers holds true in pancreatic ductal adenocarcinomaPrzemyslaw Grochowski, Bianca Grosser, Florian Sommer, et al.
Cancer Gene Therapy|November 22, 2023
Novel biomarker SARIFA in colorectal cancer: highly prognostic, not genetically driven and histologic indicator of a distinct tumor biologyNic G Reitsam, Veselin Grozdanov, Chiara M L Löffler, et al.
Journal of Pathology Informatics|June 12, 2026
SCRIPT: Stratified clinical risk prediction from pathology reports using large language modelsChiara M L Loeffler, Nic G Reitsam, Fabian Wolf, et al.
BMC Cancer|January 12, 2024
SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancerJohanna S Enke, Matthias Groß, Bianca Grosser, et al.
Pageof 3